Island Pharma Drug Cleared for Bundibugyo Ebola Use

Island Pharma Jumps 47% After Initial Approval for Ebola ...

Island Pharma drug cleared for Bundibugyo Ebola use

Island Pharma has been granted the approvals needed to allow compassionate use of its antiviral galidesivir in the Bundibugyo Ebola outbreak.

Australian company cleared to deploy drug in deadly Ebola outbreak

Island Pharmaceutical’s experimental drug will be used to treat patients in Uganda, as the African nation grapples with the deadly spread of the disease.

Island secures Ebola drug pathway

Special Report: Island Pharma’s antiviral treatment Galidesivir will be deployed to treat patients infected during the Bundibugyo Ebola virus outbreak in Uganda under a Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol.

Island Pharma gets green light to use Galidesivir in Ebola outbreak

If Galidesivir demonstrates efficacy, the program’s result may support future government procurement, biodefence stockpiling and broader commercialisation opportunities. ... The post Island Pharma gets green light to use Galidesivir in Ebola outbreak appeared first on Stockhead.

Island Pharmaceuticals (ASX:ILA) gets Uganda green light to treat live Ebola outbreak with Galidesivir

A fully funded MEURI deployment now hands Island the human efficacy data biodefence peers cannot get Island Pharmaceuticals (ASX:ILA) has just cleared every regulatory and ethics hurdle needed to deploy Galidesivir into an active Bundibugyo Ebola outbreak in Uganda. The approval covers compassionate use under the WHO’s MEURI framework, which stands for Monitored Emergency Use of Unregistered and Investigational Interventions. In plain English, i…